Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies ...
Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...
RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the ...
Alcon (ALC) and RxSight, Inc. (RXST) on Monday announced a non-exclusive collaboration to jointly develop adjustable ...
ALISO VIEJO, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following ...
In addition, numerous surgeons will present their LAL experience at the RxSight (RXST) booth in the convention exhibit hall (Booth #1911). A schedule of these presentations, which are not affiliated ...
Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units 20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 units Robust clinical data presented at ...
Many innovations have come to cataract surgery in the 25 years since Barry Emara, MD, opened his clinic in southwestern Ontario, but the fundamentals of the procedure have remained the same: inserting ...
RxSight reported Q1 2025 revenue of $37.9 million, a 28% increase, driven by higher Light Adjustable Lens sales. RxSight, Inc. reported financial results for the first quarter of 2025, highlighting a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results